Abstract: A uniform enclave interface is provided for creating and operating enclaves across multiple different types of backends and system configurations. For instance, an enclave manager may be created in an untrusted environment of a host computing device. The enclave manager may include instructions for creating one or more enclaves. An enclave may be generated in memory of the host computing device using the enclave manager. One or more enclave clients of the enclave may be generated by the enclave manager such that the enclave clients configured to provide one or more entry points into the enclave. One or more trusted application instances may be created in the enclave.

Abstract: Disclosed is a method of diagnosing and treating myeloproliferative or lymphoproliferative cell disorders, such as cancer, with chlorotoxin and/or derivatives, analogs or fragments thereof, which are effective to bind to an inhibit abnormal myeloid or lymphoid cell growth.

Abstract: This invention includes compositions and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof.

Abstract: Disclosed are stable, water-based topical creams comprising nitroglycerin and suitable for pharmaceutical and/or cosmetic use. Also disclosed are methods for preparing the creams. Also disclosed are methods for treating circulatory disorders, methods for preventing or alleviating insufficient circulation, methods for enhancing localized activity of systemically administered drugs, methods for enhancing circulation, and methods for promoting wound healing by administering the disclosed creams. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Disclosed is a method of diagnosing and treating myeloproliferative or lymphoproliferative cell disorders, such as cancer, with chlorotoxin and/or derivatives, analogs or fragments thereof, which are effective to bind to an inhibit abnormal myeloid or lymphoid cell growth.

Abstract: Disclosed is a method of treating cell proliferative disorders, such as cancer, with amounts of chlorotoxin and/or derivatives, analogs or fragments thereof, which are effective to bind to phosphoinositol phospholipids.

Abstract: The present invention is drawn to the stable cloning and expression of Nav1.9 sodium channel at the mRNA and protein levels, production of sodium channel currents characteristic of native currents in dorsal root ganglion neurons and to cell lines transiently or stably expressing recombinant Nav1.9 sodium channel.

Abstract: Disclosed is a method of treating cell proliferative disorders, such as cancer, with low doses of chlorotoxin and/or derivatives, analogs or fragments thereof, which are effective to inhibit or arrest abnormal cell growth.

Abstract: This invention includes compositions and methods for combination chemotherapy, particularly involving at least one chemotherapeutic agent used in combination with chlorotoxin or a derivative thereof.

Abstract: This invention relates to novel nonmammalian carrier vectors and viruses useful in the production of high titers of recombinant viruses which may contain foreign DNA inserts or which may be point-mutated or deleted viruses, and methods of producing those viruses. The nonmammalian carrier vector (“carrier vector”) is a chimeric vector which includes those portions of a nonmammalian virus backbone which allow replication in a nonmammalian host cell. The carrier vector includes various nucleic acid cassettes, which may include an embedded recombinant viral genome containing a desired transgene, components necessary for production of a replication-defective recombinant virus containing the transgene, and domains that permit the carrier vector to bind to mammalian cells. The invention also provides methods of producing high concentrations of recombinant virus as a substantially homogeneous. preparation, compositions to produce the recombinant virus, and novel recombinant viruses.

Abstract: This invention relates to novel nonmammalian carrier vectors and viruses useful in the production of high titers of recombinant viruses which may contain foreign DNA inserts or which may be point-mutated or deleted viruses, and methods of producing those viruses. The nonmammalian carrier vector (“carrier vector”) is a chimeric vector which includes those portions of a nonmammalian virus backbone which allow replication in a nonmammalian host cell. The carrier vector includes various nucleic acid cassettes, which may include an embedded recombinant viral genome containing a desired transgene, components necessary for production of a replication-defective recombinant virus containing the transgene, and domains that permit the carrier vector to bind to mammalian cells. The invention also provides methods of producing high concentrations of recombinant virus as a substantially homogeneous preparation, compositions to produce the recombinant virus, and novel recombinant viruses.

Abstract: The present invention provides, inter alia, recombinant chimeric nucleic acids encoding a Gag-fs-fusion partner fusion protein; a pseudovirion comprising a retroviral Gag protein and a fusion partner, wherein the fusion partner is present in a Gag-fs-fusion partner fusion protein; an immunogenic composition comprising a pseudovirion; a Gag-fs-fusion partner fusion protein; and a method of making the pseudovirions of the present invention.

Abstract: An isolated bacterium of the genus Helicobacter, characterized by the 16S ribosomal RNA encoding nucleotide sequence defined in the Sequence Listing as SEQ ID NO:1 is provided. An isolated nucleic acid having the nucleotide sequence defined in the Sequence Listing as SEQ ID NO:1 is provided. Such a nucleic acid can be used for diagnosis of infection with H. hepaticus. A nucleic acid of the present invention in a vector suitable for expression of the nucleic acid is also provided. The vector can be in a host suitable for expressing the nucleic acid. A purified antigen specific for H. hepaticus is provided. A method of making an animal model for chronic Helicobacter infection is also provided.

Abstract: Biologically active proviral molecular clones of bovine immunodeficiency-like virus and cell lines infected with the same have been prepared. Various utilities of the clones are described.